FindTrial
Sign In

CLLS52

BIOLOGICAL4 trials

Sponsors

Cellectis, Cellectis S.A.

Conditions

B-cell Acute Lymphoblastic LeukemiaB-cell Non-Hodgkin Lymphoma (B-NHL)Relapsed or refractory B-cell Acute Lymphoblastic LeukemiaRelapsed or refractory B-cell Non-Hodgkin lymphoma

Phase 1

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
RecruitingNCT04150497
Cellectis S.A.B-cell Acute Lymphoblastic Leukemia
Start: 2019-10-14End: 2026-06-30Target: 52Updated: 2025-09-09
Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma
RecruitingNCT05607420
Cellectis S.A.B-cell Non-Hodgkin Lymphoma (B-NHL)
Start: 2022-11-01End: 2027-08-31Target: 80Updated: 2025-08-24
Open-label dose-finding and dose-expansion study to evaluate the safety, expansion, persistence, and clinical activity of UCART20x22 in subjects with relapsed or refractory B-cell Non-Hodgkin Lymphoma (B-NHL)
RecruitingCTIS2022-501607-27-00
CellectisRelapsed or refractory B-cell Non-Hodgkin lymphoma
Start: 2026-01-06Target: 48Updated: 2026-01-08
Open label dose-escalation and dose-expansion study to evaluate the safety, expansion, persistence and clinical activity of UCART22 (allogeneic engineered T-cells expressing Anti-CD22 Chimeric Antigen Receptor) in patients with relapsed or refractory CD22+ B-cell Acute Lymphoblastic Leukemia (B-ALL)
Active, not recruitingCTIS2022-502305-15-00
CellectisRelapsed or refractory B-cell Acute Lymphoblastic Leukemia
Start: 2025-11-26Target: 40Updated: 2025-11-26

Related Papers

Trial in progress: Open-label dose-finding and dose-expansion study to evaluate the safety, expansion, persistence, and clinical activity of UCART20x22 in subjects with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) nathali-01
Blood2025-11-03
Preliminary Results of Nathali-01: A First-in-Human Phase I/IIa Study of UCART20x22, a Dual Allogeneic CAR-T Cell Product Targeting CD20 and CD22, in Relapsed or Refractory (R/R) Non-Hodgkin Lymphoma (NHL)
Blood2023-11-0214 citations
P1408: UPDATED RESULTS OF THE PHASE I BALLI-01 TRIAL OF UCART22, AN ANTI-CD22 ALLOGENEIC CAR-T CELL PRODUCT, IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CD22+ B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)
HemaSphere2023-08-019 citations
NATHALI‐01: A PHASE 1/2A TRIAL OF UCART20X22, AN ALLOGENEIC DUAL CAR T‐CELL THERAPY FOR PATIENTS WITH RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA (NHL)
Hematological Oncology2023-06-01
P1451: PRELIMINARY RESULTS FROM THE FLU/CY/ALEMTUZUMAB ARM OF THE PHASE I BALLI-01 TRIAL OF UCART22, AN ANTI-CD22 ALLOGENEIC CAR-T CELL PRODUCT, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) CD22+ B-CELL ALL
HemaSphere2022-06-01
Preliminary Results from the Flu/Cy/Alemtuzumab Arm of the Phase I BALLI-01 Trial of UCART22, an Anti-CD22 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Blood2021-11-0511 citations
Global Perspective on the Development of Genetically Modified Immune Cells for Cancer Therapy.
2021-02-156 citations
Preliminary Results of Balli-01: A Phase I Study of UCART22 (allogeneic engineered T-cells expressing anti-CD22 Chimeric Antigen Receptor) in Adult Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Blood2020-11-0423 citations